Literature DB >> 25027397

MicroRNAs as novel biomarkers in the diagnosis of non-small cell lung cancer: a meta-analysis based on 20 studies.

Ling Chen1, Hai Jin.   

Abstract

The detection of microRNAs (miRNAs), particularly those obtained from the bloodstream, is an emerging method for diagnosing human cancers, including non-small cell lung cancer (NSCLC). However, studies on the accuracy of miRNAs detection in diagnosing NSCLC have yield inconsistent conclusions, making it necessary to conduct a meta-analysis to systematically evaluate the diagnostic value of miRNAs in the diagnosis of NSCLC. The Medline, Embase, Chinese National Knowledge Infrastructure (CNKI), and Sinomed electronic databases were searched to identify all related articles evaluating the diagnostic value of miRNAs for NSCLC. A bivariate regression model was used to calculate the pooled diagnostic accuracy estimates. A total of 20 articles were included in this meta-analysis, involving 1,563 NSCLC patients and 1,060 healthy controls. Overall, our bivariate random effects meta-analysis yielded area under curve (AUC) of 0.85 (95 % CI: 0.82-0.88) with sensitivity of 76 % (95 CI: 72-80) and specificity of 80 % (95 % CI: 77-84) for the use of miRNAs in differentiating NSCLC patients from healthy controls. In addition, subgroup and meta-regression analyses revealed that a combination of multiple miRNAs (AUC, sensitivity, and specificity of 0.89, 81, and 84, respectively) had a higher diagnostic accuracy than single miRNA-based assays (AUC, sensitivity, and specificity of 0.81, 73, and 77 %, respectively). Furthermore, a comparison of miRNAs expression patterns between blood and sputum samples provides additional evidence that miRNAs obtained from blood (AUC, sensitivity, and specificity of 0.86, 78, and 80 %, respectively) are more credible diagnostic biomarkers than those from sputum (AUC, sensitivity, and specificity of 0.79, 66, and 79 %, respectively). In summary, the current meta-analysis suggests that the detection of miRNAs may be used in the future as an initial screening test for NSCLC, particularly, the detection of a combination of multiple miRNAs, which is a more comprehensive indicator than individual miRNAs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25027397     DOI: 10.1007/s13277-014-2188-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  44 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

3.  Small RNA regulators of gene expression.

Authors:  Joel R Neilson; Phillip A Sharp
Journal:  Cell       Date:  2008-09-19       Impact factor: 41.582

Review 4.  Measuring the accuracy of diagnostic systems.

Authors:  J A Swets
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

5.  Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer.

Authors:  Niels H H Heegaard; Aaron J Schetter; Judith A Welsh; Mitsuhiro Yoneda; Elise D Bowman; Curtis C Harris
Journal:  Int J Cancer       Date:  2011-08-26       Impact factor: 7.396

6.  Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-small Cell Lung Cancer.

Authors:  Juan Wei; Lian-Ke Liu; Wen Gao; Cheng-Jun Zhu; Yi-Qian Liu; Ting Cheng; Yong-Qian Shu
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

7.  Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer.

Authors:  Wilson H Roa; Julian O Kim; Rene Razzak; Hongfei Du; Linghong Guo; Ravinder Singh; Sayf Gazala; Sunita Ghosh; Eric Wong; Anil A Joy; James Z Xing; Eric L Bedard
Journal:  Clin Invest Med       Date:  2012-10-06       Impact factor: 0.825

8.  miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments.

Authors:  Andreas Keller; Petra Leidinger; Anne Borries; Anke Wendschlag; Frank Wucherpfennig; Matthias Scheffler; Hanno Huwer; Hans-Peter Lenhof; Eckart Meese
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

9.  Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC.

Authors:  Paola Ulivi; Giovanni Foschi; Marta Mengozzi; Emanuela Scarpi; Rosella Silvestrini; Dino Amadori; Wainer Zoli
Journal:  Int J Mol Sci       Date:  2013-05-16       Impact factor: 5.923

10.  Quantification of Plasma miRNAs by Digital PCR for Cancer Diagnosis.

Authors:  Jie Ma; Ning Li; Maria Guarnera; Feng Jiang
Journal:  Biomark Insights       Date:  2013-11-14
View more
  9 in total

1.  MicroRNA expression profiling of sputum for the detection of early and locally advanced non-small-cell lung cancer: a prospective case-control study.

Authors:  R Razzak; E L R Bédard; J O Kim; S Gazala; L Guo; S Ghosh; A Joy; T Nijjar; E Wong; W H Roa
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

Review 2.  miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC).

Authors:  Yichao Han; Hecheng Li
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  An assessment of the relationship between the expression of CCR7/CCL19 axis and selected regulatory miRNAs in non-small cell lung cancer.

Authors:  Kamila Baran; Justyna Kiszałkiewicz; Monika Migdalska-Sęk; Sławomir Jabłoński; Jacek Kordiak; Adam Antczak; Katarzyna Góralska; Ewa Brzeziańska-Lasota
Journal:  Mol Biol Rep       Date:  2019-08-28       Impact factor: 2.316

4.  Diagnostic value of strand-specific miRNA-101-3p and miRNA-101-5p for hepatocellular carcinoma and a bioinformatic analysis of their possible mechanism of action.

Authors:  Xia Yang; Yu-Yan Pang; Rong-Quan He; Peng Lin; Jie-Mei Cen; Hong Yang; Jie Ma; Gang Chen
Journal:  FEBS Open Bio       Date:  2017-12-20       Impact factor: 2.693

Review 5.  The accuracy of microRNA-210 in diagnosing lung cancer: a systematic review and meta-analysis.

Authors:  Huqin Yang; Huijuan Wang; Chao Zhang; Zhaohui Tong
Journal:  Oncotarget       Date:  2016-09-27

6.  The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers.

Authors:  Yanlong Yang; Zaoxiu Hu; Yongchun Zhou; Guangqiang Zhao; Yujie Lei; Guangjian Li; Shuai Chen; Kai Chen; Zhenghai Shen; Xiao Chen; Peilin Dai; Yunchao Huang
Journal:  Oncotarget       Date:  2017-10-04

7.  Clinically Correlated MicroRNAs in the Diagnosis of Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Min Jiang; Xuelian Li; Xiaowei Quan; Xiaoying Li; Baosen Zhou
Journal:  Biomed Res Int       Date:  2018-06-28       Impact factor: 3.411

Review 8.  Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer.

Authors:  Francesca Moretti; Paola D'Antona; Emanuele Finardi; Marco Barbetta; Lorenzo Dominioni; Albino Poli; Elisabetta Gini; Douglas M Noonan; Andrea Imperatori; Nicola Rotolo; Maria Cattoni; Paola Campomenosi
Journal:  Oncotarget       Date:  2017-10-11

Review 9.  Circulating microRNA biomarkers for lung cancer detection in Western populations.

Authors:  Haixin Yu; Zhong Guan; Katarina Cuk; Hermann Brenner; Yan Zhang
Journal:  Cancer Med       Date:  2018-09-27       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.